drugset
drugset / Trial / NCT00711958

Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients

NCT00711958 ↗

Phase 3 Completed 114 enrolled Sandoz Hexal AG · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged \>18 years who are receiving palliative chemotherapy and who are suffering from chemotherapy associated anemia. A standard treatment group (ERYPO®) will be included to provide a reference reflecting current standard medical practice.

Timeline

Start
2004-11
Primary completion
2005-07
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator epoetin alfa Protein / enzyme biologic 150 iu/kg Subcutaneous
Comparator epoetin alfa Protein / enzyme biologic 300 iu/kg Subcutaneous

Indications

anemia